Nice to see these numbers still on the shoestring of social media buzz. Now with DTC an the recent conference the wind is at our backs. Better days ahead. Soon the talk will be about worldwide dominance of a superior product. It is unbelievable to have the opportunity to grab the stock at these levels. For anyone completely frustrated last week, someday you will be asking yourself why you could not have seen past it and loaded up the boat.
Don't base your investment decisions on a low volume day or week when most of wall street are out on holiday already. I would not pay much attention to next week for the same reason. The story will unfold soon enough.
Afrezza became available on Feb 2. Six months typical for any DTC begins, which is for a period of doctor education. Today would be the six month point. Underwhelmed likely because your expectations are not based on being informed on the key dates where things would begin.
SNY inked a nice enough deal that they will see the blockbuster potential even beyond their own Toujeo and they will maximize the profitability of Afrezza. ADCOM was a fine example of that - they dominated and Afrezza received equal exposure and interest. If you have a superior product that is what you do.
They have begun the studies that will allow them to improve the labeling and claim superiority. They are marching along with creation of their own production plants and the job hiring descriptions looking for experience with inhalables has been brought to the board by multiple people in multiple countries.
Whining is senseless and selfish when the writing is all over the wall by looking around, so look around you. If a little stock manipulation on a low volume holiday week bothers you, you should not be investing in the stock market.
It is a great start. 2 Million readership. Many folks want a good chance to over and all of your shares ahead of the POP. Ignore the B.S. and be happy if you are long the stock or long term options. The rest will take care of itself soon enough.
In addition to bluecatt20, the increased negativity is the AF failed to breakdown the support yesterday at the 200 day moving average and we closed green by a nice margin. Today potentially would confirm a reversal on the daily chart. MACD bottoming and turning up. RSI has come down already after the last huge high-volume run. Chalkins Money Flow shows money is flowing in since Mid-May, while short interest has also increased. Options open interest says the battle should be at $10 not here.
Shorts are worried because volume has slowed. If good news comes they will not be able to quickly exit. They are hoping for another couple of weeks (or months) to dance in front of the fire. I could care less because they will not get any of my shares regardless of what they do, but certainly you can understand it is out of their own fear and nervousness that the stock may start to run before they have an opportunity to cover
They could care less that Afrezza will tremendously help people with diabetes. If you are a short with diabetes slamming this stock you should feel shame when you are shaving in the morning at who you see in the mirror. This is ethical investing. The shorts argument is all about greed. I hope that explains it.
Agreed, this is something that could have come out in February, but now there are many real user experiences and testimonials where the questions and hopes of the article now have exciting answers with just a little research.
Did I forget to mention A1C, the indisputable proof that Afrezza is superior than anything on the market. 8+ down to 6 and 5 non-diabetic ranges, and people taking it are saying they feel much healthier overall.
Or that you can wait until you begin eating to "just breathe", rather than guessing when the waiter or waitress might serve dinner in a crowded restaurant, and it will be out of your system as if your Pancreas is working just fine.
It is game over. This is Peter Lynch investing at it's finest. I missed buying Netflix at $5 a share when I first saw it at best buy. I have never owned it. I will not make that mistake on this one. My boat is loaded, it has been, I will continue to load up because this is an investment opportunity of a lifetime. This is a drug that will be a blockbuster worldwide.
Give me 35 percent of infinity and I will be a happy camper. ok, call me greedy. Anyone who says 35 percent of infinity is a bad deal does not understand math. Does not understand obsession with fledgling, meaningless numbers concerning a U.S. launch when factories are being built out in multiple countries and plans are being laid for a drug that will benefit the world.
By the way, MNKD enjoys these profits even beyond patent expiration in this deal. Has anyone even considered what this could mean 20x years from now? 20x years from now, still an ongoing profit stream on what has become a worldwide blockbuster. And you could own this stock under $37 a share today, a figure the stock may exceed 2 years from now.
Folks, you all have witnessed the social media buzz from early adopters. How much more will that be as Millions who still do not know of Afrezza begin to learn of it? Much, much more.
Furthermore, in their research the existing information, excitement, and testimonials on twitter, blogs, and online diabetic forums are amazing. Doctor's seminars, and prescribing doctor testimonials are now occurring. Just this week in Columbia, MO - both hospitals and Med School. The news IS getting out, and yes, TV adds will also come out. Daytime talk shows will be abuzz about Afrezza, local news stations, etc. It is going to snowball now as the year progresses.
When a drug is making such a difference that early responders are making their own commercials on youtube, there is little reason to rain on a parade with a bunch of whining when the parade is now marching.
Instead, consider enjoying the parade. The DTC parade begins, and I am happy there are two million highly interested readers that are now reading the "Just Breathe" Afrezza adds - they are about to be amazed.
Those many PWB that have not heard of Afrezza are about to hear all about Afrezza. Lives are going to be changed. A paradigm shift will soon come about.
The job postings in Ireland & Germany says that Sanofi knows where this is going. And not only has DTC begun, but now the shift is on toward ex-US expansion to other countries.
That is amazing. Thanks for sharing. Greatly exceeded my expectations about the size of the readership.
Shown on Twitter now. These magazine adds are going to prompt more local news coverage, etc., on the local news and on national talk shows. Television health experts like Dr. Oz and daytime talk shows will soon be all over this in the media, so with the Adds also come increased interest and free media coverage because it is so novel and differentiated from the needle and superior to the oral meds, some of which have the potential to be banned.
Excellent. Gonna buy five copies for my mother! On the cover or the Rolling Stone...
Hope it's a good exposure of the lies and manipulation. Can't wait
Isn't Bruce Bode Sam Finta's physician that has been blown away by his results, and change in insulin resistance?
Hope so. JMP conference presentation even mentioned potential down-blip representing the week of ADA, due to prescribing doctor's away attending the conference, followed by an uptick as a result of the heavy interest and commitment by SNY that was quite obvious to the WORLD!
JMP Conference presentation says TV adds considered and will be closer to year-end. For me, I will let them execute their plan as they have a lot going on to kick start. Doctor education seminars, Doctor Testimonials seminars where the Doctor's with prescribing experience lecture to other doctors. This will be the most effective jump start possible. Let TV Adds drive customer demand and the backside of this when the timing all comes together appropriately and Doctor's have heard these testimonials from their peers. It will all happen, so sit back an enjoy the ride.
I also feel that doctors may grace their early adopter returning patients with refills. My Doctor's have on numerous occasions got to their sample stock to save me dollars and allow me to leave with a smile.
I did not yet the latest presentations. Someone claimed 54,000 samples have been delivered. Mannkind mentioned a quarter ago they were negotiating with SNY over these samples. This means there is going to be some money in Mannkind's pocket. If they are delivered they can likely recognize it. It was stated as delivered prior to June 30th, so from an accounting perspective it is likely booked revenue in 2nd Quarter that will be reflected in next quarterly numbers.
I really do not care what this quarter's revenues are. With a slow roll-out the shift toward more buyers than sellers could also occur slowly, shorts can gradually exit, etc. - BUT MAYBE NOT. A spike in adoption will create a squeeze. The trend is our friend, slowly but surely.
With DTC beginning the adoption curve is going to have an increasing slope, and assisted by improved solutions for spirometry testing, improved insurance approval tracks, improved education of doctor's, endo's, and consumers, plus an increase in consumer demand.
In addition to these points the obsession is on numbers that were previously given on U.S. market only, and as all this takes place international rollout plans are being planned and executed. Some countries, such as New Zealand and Australia, largely recognize U.S. FDA approval so these are two countries that could come out-of-the-blue with an announcement of an opened market for Afrezza. Such things have not even been factored in yet regarding the future revenue estimates for Mannkind. When those things must be addressed by analysts an upward revaluation of the company value will occur as well.
As a patient long I can enjoy my summer and just let it happen.